Table 1 (abstract P329). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
MEDICATIONS | Time point 0 N=109 | T12 months N=109 | T24 months N=77 |
|---|---|---|---|
Any Medication | 92% | 97% | 97% |
Vascular medications | 16% | 24% | 21% |
 Endothelial receptor antagonist PDE-5-Blocker | 5% | 8% | 9% |
Corticosteroids | 52% | 44% | 44% |
All csDMARDs : | 81% | 93% | 92% |
 csDMARDs monotherapy | 61% | 66% | 60% |
 csDMARDs combination therapy | 17% | 15% | 14% |
 Methotrexate | 51% | 50% | 39% |
 Mycophenolate Mofetil | 26% | 44% | 47% |
All bDMARDs: | 5% | 14% | 18% |
 bDMARDs monotherapy | 2% | 2% | 1% |
 bDMARDs combined with csDMARDs | 3% | 12% | 17% |
 Tocilizumab | 2% | 10% | 14% |
Autologous Stem cell transplantation | 0% | 1% | 0% |